EGFR单抗的耐药机制及食管癌治疗进展  

Resistance Mechanism of EGFR mAbs and Its Application in Esophageal Cancer

作　　者：卫彬[1] 张晓慧[1] 陈小飞[1] 高勇[1] 

机构地区：[1]南京医科大学附属淮安第一医院肿瘤科,江苏淮安223300

出　　处：《医学综述》2014年第16期2939-2942,共4页Medical Recapitulate

摘　　要：表皮生长因子受体(EGFR)在多种上皮性肿瘤中过表达,其异常活化与恶性肿瘤的发生、发展密切相关。分子靶向药物EGFR单抗已经成功应用于头颈部鳞癌、结直肠癌等;但其耐药问题严重制约着临床疗效。近年来对EGFR单抗在肿瘤中的耐药机制、疗效相关的分子标志物及解决耐药策略的研究凸显重要;同时已有临床研究显示EGFR单抗在食管癌中也取得较好的临床疗效。Epidermal growth factor receptor（EGFR） is overexpressed in various epithelial tumors, and its abnormal activation is related to the occurrence and development of malignancy. Molecular targeting drug-EGFR mAbs have been successfully used in head and neck squamous cell carcinoma, colorectal cancer, etc. ; but the resistance of mAbs seriously restrict the clinical efficacy. In recent years, study on the resistance mechanism of EGFR mAbs in tumors, and their predictive molecular markers as well as the reverse method becomes more and more important, and some clinical studies has shown that EGFR mAbs could achieve good clinical efficacy in the treatment of esophageal neoplasms.

关 键 词：表皮生长因子受体 单克隆抗体 耐药 食管癌 

分 类 号：R730[医药卫生—肿瘤] R735[医药卫生—临床医学]